Drug-Eluting Stent

Concomitant chronic kidney disease and diabetes was prognostic of all-cause death and MI within 3 years among women undergoing drug-eluting stent implantation, according to new data.

Warnings about excess mortality risk with paclitaxel-coated devices to treat peripheral artery disease are “no longer supported,” based on a updated review of relevant trial data, according to an FDA announcement.

In patients with ACS, there were no differences in 5-year risk for cardiac death, MI or target lesion revascularization for those who received titanium-nitride-oxide-coated stents vs. biodegradable polymer drug-eluting stent, data show.

A drug-eluting coronary implant adaptable to vessel physiology with uncaging elements was safe and effective compared with a contemporary drug-eluting stent, demonstrating superior restoration of vessel motion and function, data show.

Comparing single antiplatelet therapy after 3-month DAPT with 12-month DAPT after PCI with third-generation DES with the thinnest struts.

Compared with metallic drug-eluting stents, a first-generation everolimus-eluting bioresorbable vascular scaffold had similar 5-year rates of death, patient-oriented composite events, angina recurrence and quality of life, data show.

NEW ORLEANS — An all-comers trial excluding patients with STEMI showed that after PCI, 3-month dual antiplatelet therapy was noninferior to 12-month DAPT for the composite outcome of net adverse clinical events, a speaker reported.

Among adults with diabetes who underwent PCI, rates of target lesion failure were similar for two drug-eluting stents, though net adverse clinical events varied between arms and differed for people taking insulin, data show.

CHICAGO — In patients who had PCI with a drug-eluting stent, dual antiplatelet therapy with indobufen plus clopidogrel was noninferior to DAPT with aspirin plus clopidogrel, according to the results of the OPTION trial.

CHICAGO — In this Healio exclusive, B. Hadley Wilson, MD, FACC, provides his perspective on several late-breaking clinical trials presented at the American Heart Association Scientific Sessions.